Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Olaparib Shows Promise in Breast Cancer Clinical Study

By BiotechDaily International staff writers
Posted on 21 Jul 2010
The chemotherapeutic agent olaparib has given promising results against advanced breast cancer in a group of women with BRCA1 (breast cancer 1, early onset) or BRCA2 (breast cancer 2, early onset) mutations in a phase two clinical trial conducted at 16 centers in Australia, Europe, and the U.S.

Olaparib is an inhibitor of the enzyme Poly ADP ribose polymerase (PARP). Patients with BRCA1/2 mutations may be genetically predisposed to develop some forms of cancer, and are often resistant to other forms of cancer treatment. Yet, this may also burden their cancers with a unique vulnerability, as these cancer cells have increased reliance on PARP to repair their DNA and enable them to continue dividing. This means that drugs that selectively inhibit PARP may be of significant benefit in patients whose cancers are susceptible to this treatment.

In the current study, a group of 54 women 18 years old or older with confirmed BRCA1 or BRCA2 mutations and recurrent, advanced breast cancer were placed into one of two test cohorts. The first cohort was treated with 400 mg oral olaparib twice daily and the second group of 27 patients received 100 mg oral olaparib twice daily.

Results published in the July 6, 2010, online edition of the journal the Lancet revealed that the higher dose appeared to have more activity against the disease, with one patient (4%) having a complete resolution of her tumor and ten (37%) showing substantial tumor shrinkage. Another 12 (44%) women had stable disease or some tumor shrinkage, but not enough to be considered a partial response by standard criteria. In the low dose group, six (22%) patients showed substantial shrinkage and 12 (44%) had some tumor shrinkage or stable disease.

Adverse side effects in the cohort given 400 mg twice daily were fatigue, nausea, vomiting, and anemia. The most frequent causally related adverse events in the cohort given 100 mg twice daily were nausea and fatigue.

"This is the first time that we have been able to take the genetic reason a person has developed cancer and make it a target,” said contributing author Dr. Susan M. Domchek, associate professor of medicine at the University of Pennsylvania School of Medicine (Philadelphia, USA). "Most of the time we look at what is going on in the tumor itself and then figure out how to target it. But in this situation, the women all had an inherited mutation in either the BRCA1 or BRCA2 gene and we could exploit that weakness in the tumor. It is a strategy that may cause fewer side effects for patients.”

"If you put too much stress on the cancer cell, it cannot take it, and it falls apart,” said Dr. Domchek. "These drugs may be very potent in tumor cells and much less toxic in normal cells. That is important from the perspective of cancer treatment. This is a different way of looking at cancer therapeutics. In oncology, this is really one of the first times that we have seen drugs being developed on the basis of inherited susceptibility – and that may open up a whole new avenue of drug development.”

Related Links:

University of Pennsylvania School of Medicine





comments powered by Disqus

Channels

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more

Business

view channel

Collaboration of Mayo Clinic and IBM Cognitive Computer Devised to Improve Clinical Trial Research

The Mayo Clinic (Rochester, MN, USA) and IBM (Armonk, NY, USA) recently announced plans to pilot Watson, the IBM cognitive computer, to match patients more rapidly with suitable clinical trials. A proof-of-concept phase is currently ongoing, with the intent to introduce it into clinical use in early 2015.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.